4-Hydroxydebrisoquine (BioDeep_00000028211)

   

human metabolite Endogenous blood metabolite


代谢物信息卡片


4-hydroxy-1,2,3,4-tetrahydroisoquinoline-2-carboximidamide

化学式: C10H13N3O (191.1058568)
中文名称: (±)4-羟基去氢异喹
谱图信息: 最多检出来源 Homo sapiens(blood) 1%

分子结构信息

SMILES: C1C(C2=CC=CC=C2CN1C(=N)N)O
InChI: InChI=1S/C10H13N3O/c11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13/h1-4,9,14H,5-6H2,(H3,11,12)

描述信息

Debrisoquine is metabolized to 4-hydroxydebrisoquine by CYP2D6. Due to this, it has been used widely to determine the hydroxylation capacity of the enzyme.(PMID:15843230) [HMDB]
Debrisoquine is metabolized to 4-hydroxydebrisoquine by CYP2D6. Due to this, it has been used widely to determine the hydroxylation capacity of the enzyme.(PMID:15843230).

同义名列表

7 个代谢物同义名

4-hydroxy-1,2,3,4-tetrahydroisoquinoline-2-carboximidamide; 3,4-Dihydro-4-hydroxy-2(1H)-isoquinolinecarboximidamide; 4-Hydroxydebrisoquin sulfate (2:1); (+/-)-3-BENZYLOXY-12-PROPANEDIOL; 4 Hydroxy debrisoquine; 4-Hydroxydebrisoquine; 4-Hydroxydebrisoquin



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(5)

BioCyc(0)

PlantCyc(0)

代谢反应

65 个相关的代谢反应过程信息。

Reactome(65)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

3 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Carley R Corado, Daniel S McKemie, Heather K Knych. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds. American journal of veterinary research. 2016 Sep; 77(9):1029-35. doi: 10.2460/ajvr.77.9.1029. [PMID: 27580115]
  • Miki Katoh, Chise Tateno, Katsutoshi Yoshizato, Tsuyoshi Yokoi. Chimeric mice with humanized liver. Toxicology. 2008 Apr; 246(1):9-17. doi: 10.1016/j.tox.2007.11.012. [PMID: 18248870]
  • Jeroen Wink, Bernadette Th Veering, Michel Kruit, Anton G L Burm, Gunilla A I Huledal, Gunilla Y Ekström, Rudolf Stienstra, Jack W van Kleef. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity. Anesthesia and analgesia. 2008 Jan; 106(1):143-6, table of contents. doi: 10.1213/01.ane.0000297293.84075.74. [PMID: 18165569]
  • Yueying Zhen, Ondrej Slanar, Kristopher W Krausz, Chi Chen, Josef Slavík, Kerry L McPhail, T Mark Zabriskie, Frantisek Perlík, Frank J Gonzalez, Jeffrey R Idle. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Drug metabolism and disposition: the biological fate of chemicals. 2006 Sep; 34(9):1563-74. doi: 10.1124/dmd.105.008920. [PMID: 16782768]
  • Paula Macedo Cerqueira, Eduardo Barbosa Coelho, Tufik José Magalhães Geleilete, Gustavo Henrique Goldman, Vera Lucia Lanchote. Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. Journal of clinical pharmacology. 2005 Dec; 45(12):1422-33. doi: 10.1177/0091270005281816. [PMID: 16291718]
  • Pedro Dorado, Roland Berecz, Macarena C Cáceres, Idilio González, Jesús Cobaleda, Adrián Llerena. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clinical chemistry and laboratory medicine. 2005; 43(3):275-9. doi: 10.1515/cclm.2005.046. [PMID: 15843230]
  • K Laine, G Tybring, S Härtter, K Andersson, J O Svensson, J Widén, L Bertilsson. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics. 2001 Oct; 70(4):327-35. doi: . [PMID: 11673748]
  • P M Cerqueira, F H Mateus, E J Cesarino, P S Bonato, V L Lanchote. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers. Journal of chromatography. B, Biomedical sciences and applications. 2000 Dec; 749(2):153-61. doi: 10.1016/s0378-4347(00)00402-3. [PMID: 11145052]
  • V A Pereira, J O Auler, M J Carmona, F H Mateus, V L Lanchote, D D Breimer, S R Santos. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2000 May; 33(5):509-14. doi: 10.1590/s0100-879x2000000500004. [PMID: 10775881]
  • P Dalén, M Dahl, K Andersson, L Bertilsson. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. British journal of clinical pharmacology. 2000 Feb; 49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x. [PMID: 10671914]
  • J O Svensson, L Bertilsson. Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. Pharmacogenetics. 1999 Aug; 9(4):529-31. doi: NULL. [PMID: 10780273]
  • P M Cerqueira, E J Cesarino, F H Mateus, Y Mere, S R Santos, V L Lanchote. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality. 1999; 11(7):591-7. doi: 10.1002/(sici)1520-636x(1999)11:7<591::aid-chir12>3.0.co;2-t. [PMID: 10423287]
  • O O Simooya, G Sijumbil, M S Lennard, G T Tucker. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. British journal of clinical pharmacology. 1998 Mar; 45(3):315-7. doi: 10.1046/j.1365-2125.1998.00671.x. [PMID: 10896408]
  • M Lanz, R Theurillat, W Thormann. Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis. Electrophoresis. 1997 Sep; 18(10):1875-81. doi: 10.1002/elps.1150181025. [PMID: 9372283]
  • R F Frye, R A Branch. Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. Journal of chromatography. B, Biomedical applications. 1996 Feb; 677(1):178-82. doi: 10.1016/0378-4347(95)00380-0. [PMID: 8925093]
  • G L Shaw, R T Falk, J Deslauriers, J N Frame, J C Nesbitt, H I Pass, H J Issaq, R N Hoover, M A Tucker. Debrisoquine metabolism and lung cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1995 Jan; 4(1):41-8. doi: NULL. [PMID: 7894323]
  • S C Mitchell, R R Shah, D G Clements, R L Smith. Changes in debrisoquine hydroxylation capacity following liver surgery. Human & experimental toxicology. 1994 Aug; 13(8):537-41. doi: 10.1177/096032719401300805. [PMID: 7946508]
  • A Bozkurt, N E Basci, A Isimer, A Sayal, S O Kayaalp. Polymorphic debrisoquin metabolism in a Turkish population. Clinical pharmacology and therapeutics. 1994 Apr; 55(4):399-401. doi: 10.1038/clpt.1994.48. [PMID: 8162666]
  • A Bozkurt, N E Basci, A Isimer, S O Kayaalp. Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction. Journal of pharmaceutical and biomedical analysis. 1993 Aug; 11(8):745-9. doi: 10.1016/0731-7085(93)80184-3. [PMID: 8257740]
  • L Bertilsson, C O Meese, Q Y Yue, M L Dahl, M Ingelman-Sundberg, I Johansson, J Säwe, M Eichelbaum. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Pharmacogenetics. 1993 Apr; 3(2):94-100. doi: 10.1097/00008571-199304000-00005. [PMID: 8100167]
  • P Lledó, A Johnston, S Walker, R M Pearson, P Turner. Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios. Human & experimental toxicology. 1993 Mar; 12(2):161-3. doi: 10.1177/096032719301200212. [PMID: 8096716]
  • L Bertilsson, Y Q Lou, Y L Du, Y Liu, T Y Kuang, X M Liao, K Y Wang, J Reviriego, L Iselius, F Sjöqvist. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clinical pharmacology and therapeutics. 1992 Apr; 51(4):388-97. doi: 10.1038/clpt.1992.38. [PMID: 1345344]
  • S Sardas, J Pontin, J R Idle. Polymorphic 4-hydroxylation of debrisoquine in a Turkish population. Pharmacogenetics. 1991 Nov; 1(2):123-4. doi: 10.1097/00008571-199111000-00013. [PMID: 1844871]
  • L Daumas, J F Sabot, E Vermeulen, P Clapot, F Allegre, H Pinatel, M Boucherat, B Francois. Determination of debrisoquine and metabolites in human urine by gas chromatography-mass spectrometry. Journal of chromatography. 1991 Sep; 570(1):89-97. doi: 10.1016/0378-4347(91)80203-o. [PMID: 1797839]
  • M E Veronese, S McLean. Debrisoquine oxidation polymorphism in a Tasmanian population. European journal of clinical pharmacology. 1991; 40(5):529-32. doi: 10.1007/bf00315235. [PMID: 1884730]
  • T Y Kuang, X M Liao, K Y Wang, Y Zhang, Y Q Lou. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers]. Yao xue xue bao = Acta pharmaceutica Sinica. 1991; 26(4):250-4. doi: NULL. [PMID: 1957669]
  • I G Nikolov, I N Chernozemsky, J R Idle. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. IARC scientific publications. 1991; ?(115):289-96. doi: . [PMID: 1820343]
  • J Kallio, R Huupponen, J Viikari. Debrisoquine hydroxylation polymorphism in diabetic patients. Diabetes research (Edinburgh, Scotland). 1990 Nov; 15(3):125-9. doi: NULL. [PMID: 2132205]
  • K A Johnson, V Kolatkar, R J Straka. Improved selectivity of a high-performance liquid chromatography assay for debrisoquine and its 4-hydroxy metabolite from urine. Therapeutic drug monitoring. 1990 Sep; 12(5):478-80. doi: 10.1097/00007691-199009000-00012. [PMID: 2293411]
  • X M Xu, W D Jiang. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1990 Sep; 11(5):385-8. doi: NULL. [PMID: 2130590]
  • L F Jorge, T D Arias, T Inaba, P R Jackson. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama. British journal of clinical pharmacology. 1990 Aug; 30(2):281-5. doi: 10.1111/j.1365-2125.1990.tb03776.x. [PMID: 2206790]
  • M N Meillard, D Bentué-Ferrer, F Brunet-Bourgin, G Morel, H Allain. [Hydroxylation of debrisoquin in Parkinson's disease]. Presse medicale (Paris, France : 1983). 1990 May; 19(20):947-9. doi: NULL. [PMID: 2141131]
  • J Kallio. The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method. International journal of clinical pharmacology, therapy, and toxicology. 1990 May; 28(5):223-6. doi: NULL. [PMID: 2163994]
  • S Wanwimolruk, P Patamasucon, E J Lee. Evidence for the polymorphic oxidation of debrisoquine in the Thai population. British journal of clinical pharmacology. 1990 Feb; 29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x. [PMID: 2306417]
  • Y L Du, Y Q Lou. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1990 Jan; 11(1):7-10. doi: . [PMID: 2403020]
  • Y Horai, J Taga, T Ishizaki, K Ishikawa. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. British journal of clinical pharmacology. 1990 Jan; 29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x. [PMID: 2297455]
  • C J Speirs, S Murray, D S Davies, A F Biola Mabadeje, A R Boobis. Debrisoquine oxidation phenotype and susceptibility to lung cancer. British journal of clinical pharmacology. 1990 Jan; 29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x. [PMID: 2153391]
  • E Spina, A L Buemi, E Sanz, L Bertilsson. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. Therapeutic drug monitoring. 1989 Nov; 11(6):721-3. doi: 10.1097/00007691-198911000-00019. [PMID: 2595755]
  • F Derenne, C Joanne, S Vandel, G Bertschy, R Volmat, P Bechtel. Debrisoquine oxidative phenotyping and psychiatric drug treatment. European journal of clinical pharmacology. 1989; 36(1):53-8. doi: 10.1007/bf00561023. [PMID: 2563689]
  • P Seideman, G Alván. Debrisoquine hydroxylation phenotype in SLE patients. Scandinavian journal of rheumatology. 1989; 18(1):63-4. doi: 10.3109/03009748909095406. [PMID: 2704985]
  • N Caporaso, L W Pickle, S Bale, R Ayesh, M Hetzel, J Idle. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Genetic epidemiology. 1989; 6(4):517-24. doi: 10.1002/gepi.1370060406. [PMID: 2777072]
  • D K Sommers, J Moncrieff, J Avenant. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Human toxicology. 1989 Jan; 8(1):39-43. doi: 10.1177/096032718900800107. [PMID: 2714809]
  • J Kallio, R Lindberg, R Huupponen, E Iisalo. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. British journal of clinical pharmacology. 1988 Dec; 26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x. [PMID: 3242585]
  • G K Scadding, R Ayesh, J Brostoff, S C Mitchell, R H Waring, R L Smith. Poor sulphoxidation ability in patients with food sensitivity. BMJ (Clinical research ed.). 1988 Jul; 297(6641):105-7. doi: 10.1136/bmj.297.6641.105. [PMID: 3408928]
  • J Benítez, A LLerena, J Cobaleda. Debrisoquin oxidation polymorphism in a Spanish population. Clinical pharmacology and therapeutics. 1988 Jul; 44(1):74-7. doi: 10.1038/clpt.1988.115. [PMID: 3391005]
  • J Moncrieff. Assay of debrisoquine and 4-hydroxydebrisoquine in urine by reversed-phase high-performance liquid chromatography using on-line sample clean-up on a standard isocratic chromatograph. Journal of chromatography. 1988 Jun; 428(1):178-82. doi: 10.1016/s0378-4347(00)83905-5. [PMID: 3170673]
  • W K Amery, P T Davies, L I Caers, J Heykants, T J Steiner, R Woestenborghs, F C Rose. Hepatic cytochrome P450-mediated oxidation function in migraine. Cephalalgia : an international journal of headache. 1988 Jun; 8(2):71-4. doi: 10.1046/j.1468-2982.1988.0802071.x. [PMID: 3401919]
  • D K Sommers, J Moncrieff, J Avenant. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Human toxicology. 1988 May; 7(3):273-6. doi: 10.1177/096032718800700308. [PMID: 3391625]
  • K Chan. Comparison of gas chromatographic and high-performance liquid chromatographic assays for the determination of debrisoquine and its 4-hydroxy metabolite in human fluids. Journal of chromatography. 1988 Mar; 425(2):311-21. doi: 10.1016/0378-4347(88)80035-5. [PMID: 3372645]
  • C O Meese, C Fischer, M Eichelbaum. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry. Biomedical & environmental mass spectrometry. 1988 Jan; 15(2):63-6. doi: 10.1002/bms.1200150202. [PMID: 3349209]
  • E J Lee. Diurnal effects on debrisoquine hydroxylation phenotyping. European journal of clinical pharmacology. 1988; 35(4):441-2. doi: 10.1007/bf00561381. [PMID: 3197754]
  • C O Meese, P Thalheimer, M Eichelbaum. High-performance liquid chromatographic method for the analysis of debrisoquine and its S-(+)- and R-(-)-hydroxy metabolites in urine. Journal of chromatography. 1987 Dec; 423(?):344-50. doi: 10.1016/0378-4347(87)80362-6. [PMID: 3443671]
  • D Decolin, A Nicolas, N Motassim, G Siest. Direct determination of debrisoquine and 4-hydroxydebrisoquine using a high-performance liquid chromatographic switching technique. Journal of chromatography. 1987 Aug; 419(?):469-74. doi: 10.1016/0378-4347(87)80318-3. [PMID: 3667807]
  • P A Philip, H J Rogers, P G Harper. Acetylation and oxidation phenotypes in malignant lymphoma. Cancer chemotherapy and pharmacology. 1987; 20(3):235-8. doi: 10.1007/bf00570492. [PMID: 3677298]
  • K Róna, L Vereczkey, B Gachályi. Liquid chromatographic method for the determination of debrisoquine and its 4-hydroxy metabolite in human urine. Journal of chromatography. 1986 Jun; 378(2):509-13. doi: 10.1016/s0378-4347(00)80752-5. [PMID: 3734009]
  • B Mellström, J Säwe, L Bertilsson, F Sjöqvist. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clinical pharmacology and therapeutics. 1986 Apr; 39(4):369-71. doi: 10.1038/clpt.1986.56. [PMID: 3956053]
  • R L Woosley, D M Roden, G H Dai, T Wang, D Altenbern, J Oates, G R Wilkinson. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clinical pharmacology and therapeutics. 1986 Mar; 39(3):282-7. doi: 10.1038/clpt.1986.40. [PMID: 3081292]
  • P M Harrison, A M Tonkin, S T Dixon, A J McLean. Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography. Journal of chromatography. 1986 Jan; 374(1):204-8. doi: 10.1016/s0378-4347(00)83273-9. [PMID: 3949931]
  • B E Westwood, P J Harman, M L Mashford. Liquid chromatographic assay for debrisoquine and 4-hydroxydebrisoquine in urine. Journal of chromatography. 1986 Jan; 374(1):200-3. doi: 10.1016/s0378-4347(00)83272-7. [PMID: 3949930]
  • K Nakamura, F Goto, W A Ray, C B McAllister, E Jacqz, G R Wilkinson, R A Branch. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical pharmacology and therapeutics. 1985 Oct; 38(4):402-8. doi: 10.1038/clpt.1985.194. [PMID: 4042523]
  • J C McGourty, J H Silas, J J Fleming, A McBurney, J W Ward. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clinical pharmacology and therapeutics. 1985 Oct; 38(4):409-13. doi: 10.1038/clpt.1985.195. [PMID: 2864157]
  • N M Woolhouse, M Eichelbaum, N S Oates, J R Idle, R L Smith. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clinical pharmacology and therapeutics. 1985 May; 37(5):512-21. doi: 10.1038/clpt.1985.81. [PMID: 3987174]
  • P J Wedlund, W S Aslanian, C B McAllister, G R Wilkinson, R A Branch. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clinical pharmacology and therapeutics. 1984 Dec; 36(6):773-80. doi: 10.1038/clpt.1984.256. [PMID: 6499356]
  • E Spina, C Birgersson, C von Bahr, O Ericsson, B Mellström, E Steiner, F Sjöqvist. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clinical pharmacology and therapeutics. 1984 Nov; 36(5):677-82. doi: 10.1038/clpt.1984.239. [PMID: 6488689]
  • G Karlaganis, A Küpfer, R Preisig. Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation. British journal of clinical pharmacology. 1984 Apr; 17(4):470-3. doi: 10.1111/j.1365-2125.1984.tb02374.x. [PMID: 6721994]
  • T P Sloan, R Lancaster, R R Shah, J R Idle, R L Smith. Genetically determined oxidation capacity and the disposition of debrisoquine. British journal of clinical pharmacology. 1983 Apr; 15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x. [PMID: 6849780]
  • L Bertilsson, A Aberg-Wistedt. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. British journal of clinical pharmacology. 1983 Mar; 15(3):388-90. doi: 10.1111/j.1365-2125.1983.tb01518.x. [PMID: 6849771]
  • P H Chapman, M D Rawlins, S Shuster, J R Idle, J C Ritchie, R L Smith. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis. European journal of clinical pharmacology. 1981; 21(3):257-8. doi: 10.1007/bf00627929. [PMID: 6895622]